The single procedure success rates of durable PVI for paroxysmal AF varies between 80% and 90%. This prospective, randomised controlled, non-inferiority study (NCT00774566), presented by Dr Bastian Kaiser (Robert-Bosch-Hospital Bad Cannstatt, Germany), investigated the efficacy of cryoballoon PVI versus PVI with radiofrequency energy following the CLOSE protocol in terms of single-procedure, arrhythmia-free outcome, safety, and procedural time.
The study enrolled and randomised 150 patients undergoing de-novo PVI for paroxysmal AF. In group A (n=75), PVI was performed using a 23 or 28 mm cryoballoon. In group B (n=75), ablation was performed with radiofrequency energy according to the CLOSE protocol. Follow-up was after 3 months and at the end of the study period (mean 14±2 months). The primary endpoint was arrhythmia-free survival.
The procedural time in group A was statistically significantly shorter than in group B (70.53 min vs 115.35 min; P<0.01), while fluorescence time and dose area product did not differ between groups. Both procedures were performed with a low number of complications.
Results showed that cryoballoon PVI and PVI using ablation index following the CLOSE protocol are equally efficient in achieving durable PVI (PV recovery in 2.67% vs 4%; P=ns). Cryoballoon ablation led to significantly more AF recurrence during the blanking period of 3 months (P=0.048), most likely due to the higher myocardial damage by the cryoballoon, a theory supported by higher corresponding troponin levels. At the end of the 14-month follow-up, the difference between treatment group was not detectable anymore (P=0.110).
- Kaiser B. Pulmonary vein isolation using cryoballoon ablation versus RF ablation using ablation index following the CLOSE protocol: a prospective randomised trial. EHRA 2021 Congress, 23-25 April.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Pulmonary vein isolation lesions plus personalised methods shows promising results Next Article
Personalised pulmonary vein isolation procedure feasible and effective »
« Pulmonary vein isolation lesions plus personalised methods shows promising results Next Article
Personalised pulmonary vein isolation procedure feasible and effective »
Table of Contents: EHRA 2021
Featured articles
Atrial Fibrillation and Direct Oral Anticoagulant
Predictors of young-onset atrial fibrillation
RACE 3 long-term results show fading benefit of targeted therapies in AF and HF
Deep dive into EAST-AFNET 4 results on early rhythm-control in atrial fibrillation
Cryo-FIRST study: improved AF and QoL outcomes with cryoballoon versus drug therapy
STROKESTOP: Benefits of systematic screening for atrial fibrillation
DOACs and bleeding: the role of antidotes
2021 EHRA practical guide: DOACs in pre-operative and bleeding patients
Atrial Ablation
Early rhythm-control ablation: insight from the CHARISMA registry
Personalised pulmonary vein isolation procedure feasible and effective
Pulmonary vein isolation: cryoballoon non-inferior to radiofrequency ablation
Diagnostic Tools
EHRA Practical Guide on cardiac imaging in electrophysiology
Novel diagnostic score accurately differentiates between athlete’s heart and ARVC
The precordial R-prime wave: a discriminator between cardiac sarcoidosis and ARVC
Limited added value of ECG-based mortality prediction in COVID-19 patients using machine learning
Devices
EHRA expert statement on pacemakers and intracardial devices: “watch out for the little old lady”
5-Year efficacy of subcutaneous implantable cardioverter defibrillator
Specific Populations
Individualised approaches key to success in resynchronisation therapy non-responders
Antiarrhythmic drug treatment in children: evidence-based recommendations
The importance of cardiac imaging in patients with congenital heart disease
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com